📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 16:18
1 analysed today
FollowTelegram
1
Today
151,445
All-time analysed
43,380
Positive
6,733
Negative
92,520
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Rs 0.57 Cr Net Loss in Q1 FY27 as Material Costs Exceed Revenue
Shree Ganesh Biotech reported a net loss of Rs 0.57 Cr for the quarter ended June 30, 2026, a sharp reversal from a profit of Rs 0.33 Cr in the same period last year. While revenue from operations grew marginally by 3.3% YoY to Rs 1.43 Cr, it fell 32.6% sequentially from the March 2026 quarter. A critical concern is that the cost of materials consumed (Rs 1.87 Cr) exceeded the total revenue from sales (Rs 1.43 Cr), leading to negative gross margins. The company's losses have widened for the second consecutive quarter.
Confidence: HIGH
What changedThe company has swung from a profitable position a year ago to a widening loss, primarily due to material costs rising faster than sales.
Why it mattersFor a micro-cap company with a market cap of only Rs 14 Cr, a quarterly loss of Rs 0.57 Cr is significant (approx. 4% of market cap) and indicates severe operational stress.
Q1 Revenue from Operations: Rs 142.99 lacsQ1 Net Loss: Rs 57.32 lacsMaterial Cost vs Revenue: 130.5%QoQ Revenue Growth: -32.6%Revenue vs TTM Revenue: ~28.6%
📅 Short termThe stock is likely to face downward pressure as the market reacts to the widening losses and negative gross margins.
📈 Long termThe long-term outlook remains weak unless the company can restructure its operations to ensure that basic material costs do not exceed sales value.
⚠ Risk flags
- Material costs exceeding revenue
- Widening quarterly losses
- Micro-cap liquidity risk
- Negative operating margins
Key Highlights
Net loss of Rs 57.32 lacs in Q1 FY27 compared to a profit of Rs 32.70 lacs in Q1 FY26
Revenue from operations declined 32.6% QoQ to Rs 142.99 lacs from Rs 212.13 lacs
Cost of materials consumed stood at Rs 186.67 lacs, representing 130.5% of sales revenue
Total expenses rose to Rs 232.32 lacs, up from Rs 147.19 lacs in the year-ago quarter
Earnings Per Share (EPS) turned negative at Rs -0.01 for the quarter
👀 What to Watch
Investors should monitor the company's ability to manage raw material procurement costs, as the current cost structure is unsustainable with expenses exceeding revenue. Watch for any management commentary on pricing power or supply chain issues in upcoming filings.
Rs 0.57 Cr Net Loss in Q1 FY27; Revenue declines 32.6% QoQ
Shree Ganesh Biotech reported a net loss of Rs 0.57 Cr for Q1 FY27, a significant deterioration from a profit of Rs 0.33 Cr in the same quarter last year. Revenue from operations fell 32.6% sequentially to Rs 1.43 Cr from Rs 2.12 Cr in the March 2026 quarter. A critical concern is that cost of materials consumed (Rs 1.87 Cr) alone exceeded the total revenue from operations (Rs 1.43 Cr). With a market cap of only Rs 14 Cr, these losses represent a meaningful erosion of value relative to the company's size.
Confidence: HIGH
What changedThe company has swung from a marginal profit to a significant loss as operational costs, specifically material inputs, have surged past total sales.
Why it mattersFor a micro-cap company with a Rs 14 Cr market cap, a quarterly loss of Rs 0.57 Cr is substantial and indicates severe pressure on the business model where input costs are not being recovered through sales.
Net Loss (Q1 FY27): Rs 57.32 lacsRevenue (Q1 FY27): Rs 142.99 lacsMaterial Cost to Revenue: 130.5%QoQ Revenue Growth: -32.6%Market Cap: Rs 14 Cr
📅 Short termThe stock is likely to face downward pressure in the coming weeks as the market reacts to the widening losses and the fact that material costs are higher than revenue.
📈 Long termLimited; the company's structural viability is at risk if it cannot bring material costs below revenue levels and reverse the trend of widening losses.
⚠ Risk flags
- Material costs exceeding revenue
- Widening quarterly losses
- Negative operating margins
- Micro-cap liquidity risk
Key Highlights
Net loss of Rs 57.32 lacs in Q1 FY27 compared to a profit of Rs 32.70 lacs in Q1 FY26
Revenue from operations declined 32.6% QoQ to Rs 142.99 lacs from Rs 212.13 lacs
Cost of materials consumed at Rs 186.67 lacs represents 130.5% of revenue from operations
Total expenses rose to Rs 232.32 lacs, leading to a loss before tax of Rs 57.32 lacs
Earnings Per Share (EPS) turned negative at Rs (0.01) for the quarter
👀 What to Watch
Watch for management commentary regarding the spike in material costs which now exceed total sales, and monitor if the company can stabilize its operating margins which are currently deeply negative.
